Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the myocardial infarction market grown over the years?
The market for myocardial infarction has witnessed significant growth in the past few years. The market size is forecasted to rise from $2.05 billion in 2024 to $2.2 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. Factors such as the development of beta-blockers, the establishment of specialized chest pain centers, advancements in thrombolytic treatments, personalized medicine strategies, and the use of wearable cardiovascular devices have contributed to this historical growth.
What Is the forecasted market size and growth rate for the myocardial infarction market?
The market size for myocardial infarctions is predicted to experience robust expansion in the upcoming years, reaching $2.94 billion in 2029 with a 7.5% compound annual growth rate (CAGR). This planned expansion during the forecast period is reflective of the global health initiatives related to cardiovascular health, wider availability of reperfusion therapies, the emergence of RNA therapeutics for cardiovascular conditions, increased emphasis on patient-focused therapy modules, concentration on microvascular dysfunction, and advancement in bioelectronic medicine. Key market trends throughout this period encompass progress in cardiovascular imaging, better cardiac surgery techniques, telemedicine enhancements, use of artificial intelligence in diagnostics, the emergence of digital biomarkers for risk evaluation, the adoption of blockchain technology for secure health data, artificial intelligence-aided drug discovery, and new innovations in cardiac rehabilitation technologies.
Get your myocardial infarction market report here!
https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report
What are the major factors driving growth in the myocardial infarction market?
The myocardial infarction market is expected to expand due to a rising number of smokers. Tobacco use, via cigarettes, cigars, or pipes, is a contributing factor to myocardial infarction as the substances in cigarette smoke cause the blood to coagulate and form clots in blood vessels which can lead to a blockage. To highlight, Office for National Statistics pointed out in September 2023 that the majority of smokers in the UK, with around 16.3% or 1.4 million individuals, were between the ages of 25 and 34 in 2022, a rise from the 15.8%, or roughly 1.3 million people from the past year. Consequently, this surge in smoking incidence is fueling the upswing of the myocardial infarction market.
What key areas define the segmentation of the global myocardial infarction Market?
The myocardial infarction market covered in this report is segmented –
1) By Drug Class: Antiplatelet Agents, Glycoprotein IIb Or IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin-Receptor Blockers, Analgesics, Thrombolytics
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor
2) By Glycoprotein IIb Or IIIa Inhibitors: Abciximab, Eptifibatide, Tirofiban
3) By Antithrombotic Agents: Heparins, Direct Oral Anticoagulants (DOACs)
4) By Beta-Adrenergic Blockers: Metoprolol, Carvedilol
5) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate
6) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Lisinopril, Enalapril
7) By Angiotensin-Receptor Blockers: Losartan, Valsartan
8) By Analgesics: Morphine, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
9) By Thrombolytics: Alteplase, Reteplase
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12164&type=smp
What are the top market players propelling the growth of the myocardial infarction industry?
Major companies operating in the myocardial infarction market include Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS
What are the key trends shaping the future of the myocardial infarction market?
The myocardial infarction market is seeing significant advancements as prominent companies concentrate on creating new-age drugs such as anti-inflammatory medications for targeted treatment of cardiovascular inflammation, aiming to secure a competitive advantage. Anti-inflammatory drugs serve to reduce inflammation by focusing on the body’s immune response, thereby relieving pain and swelling. Take for example, Agepha Pharma, a medical product manufacturing company based in Slovakia. In June 2023, the company gained FDA approval for its drug, Lodoco (colchicine), the first of its kind anti-inflammatory drug designed to target the root cause of atherosclerotic cardiovascular disease. Lodoco, formulated to reduce the risk factors of myocardial infarction, stroke, coronary revascularization and cardiovascular related deaths in adults, can either be used by itself or combined with cholesterol-lowering medications. In clinical trials, this reformulated low-dose colchicine showed a clear 31% decrease in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12164
What regions are dominating the myocardial infarction market growth?
North America was the largest region in the myocardial infarction market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Legal Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/legal-services-global-market-report
Professional Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/professional-services-global-market-report
Software And BPO Services Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/software-and-bpo-services-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
